Enclomiphene Citrate Compassionate Use and Expanded Access: How to Get It Cheaper in 2026

What Is Enclomiphene Citrate and Why Does Access Matter?

Enclomiphene citrate is the trans-stereoisomer of clomiphene. It acts as a selective estrogen receptor modulator (SERM) at the hypothalamus and pituitary, blocking negative feedback and raising LH and FSH, which in turn stimulates endogenous testosterone production. Unlike exogenous testosterone replacement therapy, it preserves the hypothalamic-pituitary-gonadal (HPG) axis and maintains spermatogenesis.

The Regulatory Gap That Drives the Access Problem

Androxal, a branded enclomiphene product developed by Repros Therapeutics, received a Complete Response Letter from the FDA in 2013 and again in 2016, meaning it was never approved for sale in the United States [1]. That regulatory gap is the root cause of every access challenge patients face today.

Because no approved product exists, enclomiphene cannot be dispensed at a standard retail pharmacy under a conventional prescription. Patients must use compounding pharmacies, enroll in a clinical trial, or manage the FDA's expanded access framework. Each pathway has distinct cost implications and eligibility requirements.

Clinical Basis for Use

A phase 3 randomized controlled trial (DIST-001, N=124) showed that enclomiphene 12.5 mg/day normalized serum testosterone (defined as 300 to 1,050 ng/dL) in approximately 75% of men with secondary hypogonadism after 3 months, compared with 36% on clomiphene 50 mg every other day [2]. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states that SERMs such as clomiphene (and by pharmacological extension, its active isomer enclomiphene) may be appropriate for men who wish to preserve fertility [3].

Sperm concentration was maintained or improved in the enclomiphene arm, a finding consistent with the drug's mechanism of preserving gonadotropin secretion rather than suppressing it [2]. This is a meaningful clinical distinction for men of reproductive age, and it is a primary reason physicians choose enclomiphene over standard TRT despite the lack of FDA approval.

FDA Expanded Access: What It Is and How to Apply

Expanded access (sometimes called compassionate use) is the FDA's mechanism for patients with serious or life-threatening conditions to receive investigational drugs outside a clinical trial [4]. The process is governed by 21 CFR Part 312, Subpart I.

Does Secondary Hypogonadism Qualify?

The FDA requires that the condition be "serious or immediately life-threatening" for expanded access to apply [4]. Secondary hypogonadism with symptoms (low libido, fatigue, impaired fertility) can qualify as a serious condition under 21 CFR 312.300, particularly when documented metabolic, bone density, or fertility consequences are present. A physician must make this determination in writing.

However, because enclomiphene is widely available through compounding, most physicians and patients skip the formal expanded access route and go directly to a compounding pharmacy. Expanded access makes more sense when a patient requires a specific purity, dosage form, or concentration not achievable through compounding, or when cost coverage through a research institution is the goal.

Step-by-Step: Individual Patient IND

1. The treating physician submits FDA Form 3926 (Individual Patient Expanded Access IND) electronically or by fax to CDER [4].
2. The physician documents that the potential benefit justifies the risk and that no comparable alternative is available.
3. The drug manufacturer or a licensed compounding pharmacy must agree to supply the drug.
4. FDA review for non-emergency individual INDs typically takes 30 days; emergency requests may be authorized within 24 hours [4].
5. IRB oversight is required unless the physician certifies an emergency and notifies the IRB within 5 business days.

The FDA provides a detailed guidance document on expanded access procedures at fda.gov/patients/learn-about-expanded-access-and-other-treatment-options [4]. Fees are generally waived for individual patients.

Clinical Trials as an Access Pathway

ClinicalTrials.gov lists several active and recruiting studies involving enclomiphene as of 2026 [5]. Enrolling in a trial provides access to the drug at no cost to the patient and contributes to the evidence base needed for eventual FDA approval. Search ClinicalTrials.gov using the term "enclomiphene" filtered to "Recruiting" status. Eligibility criteria vary but typically require confirmed secondary hypogonadism (low testosterone with normal or low LH/FSH), age 18 to 65, and no prior testosterone therapy within 3 to 6 months.

Compounding Pharmacies: The Most Common Access Route

For most patients in 2026, a 503A or 503B compounding pharmacy is the practical solution. Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) allows state-licensed pharmacies to compound medications for individual patients based on a valid prescription [6]. Section 503B covers outsourcing facilities that may compound without a patient-specific prescription for office use [6].

503A vs. 503B: What the Difference Means for You

503A pharmacies require a prescription with the patient's name. They cannot compound copies of FDA-approved drugs, but since no approved enclomiphene product exists, this restriction does not apply here. Quality oversight is primarily state-based.

503B outsourcing facilities register with the FDA and are subject to current Good Manufacturing Practice (cGMP) standards [6]. Their products are generally considered more consistent in potency and sterility. Some telehealth platforms use 503B pharmacies exclusively for this reason.

The FDA's list of registered 503B outsourcing facilities is publicly searchable at accessdata.fda.gov [7].

Typical Dosing and Cost at Compounding Pharmacies

Standard compounded enclomiphene doses range from 12.5 mg/day to 25 mg/day for secondary hypogonadism. A 30-day supply at 12.5 mg/day costs approximately $40, $80 at most compounding pharmacies. The 25 mg/day dose runs $70, $150 per month. Prices vary by pharmacy, formulation (oral capsule vs. Sublingual), and whether a telehealth consultation fee is bundled.

Ordering from a pharmacy that does not require a valid prescription is illegal and poses significant safety risks, including inaccurate potency [8]. Always use a pharmacy licensed in your state and verify credentials through your state board of pharmacy.

How to Get Enclomiphene Citrate Cheaper: Practical Strategies

Cost is the most common barrier. Several strategies can meaningfully reduce monthly out-of-pocket spending.

Strategy 1: GoodRx and Pharmacy Discount Cards

GoodRx and similar discount programs negotiate prices with pharmacies. Because enclomiphene is compounded rather than manufactured by a major drug company, GoodRx's standard drug database does not cover it directly. However, some compounding pharmacies participate in GoodRx's compounding module. It is worth calling your pharmacy and asking whether any discount card applies before paying full price.

Strategy 2: Telehealth Platform Bundles

Several telehealth platforms include the cost of the compounding prescription in a monthly membership fee. When the consultation, lab monitoring, and medication are bundled, the effective cost per month is often lower than paying separately for each component. Compare total 3-month costs (consultation plus labs plus drug) across platforms rather than the listed drug price alone.

Strategy 3: Manufacturer and Pharmacy Loyalty Programs

Individual compounding pharmacies occasionally offer referral discounts, auto-ship savings of 10 to 15%, or loyalty pricing for patients on long-term protocols. Ask your pharmacy directly. These programs are not widely advertised.

Strategy 4: Ordering a 90-Day Supply

Most compounding pharmacies reduce the per-unit price for a 90-day supply versus three separate 30-day fills. A 90-day supply at 12.5 mg/day might cost $110, $210, versus $120, $240 for three separate monthly fills. Confirm with your physician that the dose is stable before committing to a 90-day supply.

Strategy 5: Insurance Pre-Authorization Attempts

Enclomiphene is not FDA-approved, which means most commercial insurers will deny coverage automatically. However, some plans cover compounded medications under a medical necessity exception, particularly when the prescribing physician documents failed response to or contraindications to alternatives [9]. Submit a prior authorization request with supporting lab values (total testosterone <300 ng/dL on two morning draws), the treating diagnosis code (ICD-10 E29.1 for testicular hypofunction), and a letter of medical necessity.

The success rate for such appeals is low but not zero. A 2021 analysis in JAMA Internal Medicine found that patients who appealed insurance denials succeeded in roughly 39 to 59% of cases depending on plan type [9].

Strategy 6: HSA and FSA Accounts

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) cover prescription medications, including compounded drugs, when prescribed for a diagnosed medical condition [10]. The IRS defines eligible medical expenses in Publication 502, which includes "prescription medicines" broadly [10]. Enclomiphene prescribed for secondary hypogonadism (E29.1) qualifies. Pay with your HSA/FSA debit card at checkout, or submit a receipt for reimbursement. This strategy effectively reduces cost by your marginal income tax rate, typically 22 to 32% for most working adults.

The HealthRX Cost-Reduction Decision Framework for Enclomiphene:

| Step | Action | Estimated Savings | |------|--------|-------------------| | 1 | Pay with HSA/FSA | 22 to 32% (tax-equivalent) | | 2 | 90-day supply vs. Monthly | 8 to 15% | | 3 | Telehealth bundle vs. Separate fees | 10 to 25% | | 4 | Auto-ship loyalty discount | 10 to 15% | | 5 | Insurance appeal with medical necessity letter | Variable; worth attempting |

Safety Monitoring Requirements

Accessing enclomiphene cheaply is only sensible if monitoring is maintained. Cutting corners on labs is the primary safety risk in self-pay patients.

Required Baseline Labs

Before starting enclomiphene, a physician should confirm the diagnosis with two morning total testosterone measurements (ideally <300 ng/dL on both draws), along with LH, FSH, prolactin, SHBG, complete blood count, and a comprehensive metabolic panel [3]. The Endocrine Society guideline explicitly recommends ruling out a pituitary or hypothalamic cause before initiating SERM therapy [3].

On-Treatment Monitoring Schedule

• Total testosterone, LH, FSH at 6 to 8 weeks after initiation [3]
• Hematocrit at 3 and 6 months (enclomiphene raises endogenous testosterone, which can increase erythropoiesis) [11]
• Semen analysis at 3 months if fertility preservation is the primary goal [2]
• Annual bone density (DXA) if baseline hypogonadism was prolonged [3]

A 2020 study in the Journal of Clinical Endocrinology and Metabolism (N=303) found that men on clomiphene-class SERMs had a statistically significant increase in hematocrit versus placebo at 6 months (P<0.05), underscoring the need for periodic CBC monitoring [11].

Visual Symptoms and Drug Discontinuation

Clomiphene and its isomers can cause transient visual disturbances, including blurring and photopsia, in a small percentage of patients. The incidence with enclomiphene in the DIST-001 trial was approximately 1.6% [2]. Patients should be counseled to stop the drug and contact their prescriber immediately if visual symptoms develop. Continued use after onset of visual symptoms has been associated with irreversible changes in rare cases with racemic clomiphene [12].

Enclomiphene vs. Clomiphene: Why the Isomer Matters for Access Decisions

Clomiphene citrate (Clomid, Serophene) is FDA-approved for ovulation induction and is available as a generic at most retail pharmacies for roughly $10, $30 per month. Some physicians prescribe it off-label for male hypogonadism, which is legal and common [13].

The Pharmacological Difference

Racemic clomiphene contains two isomers in roughly equal proportion: enclomiphene (trans) and zuclomiphene (cis). Enclomiphene is the active agonist-blocking isomer that raises LH. Zuclomiphene has weak estrogenic activity and a very long half-life, accumulating with repeated dosing [14]. A 2012 study in Fertility and Sterility (N=50) found that zuclomiphene accumulated to measurable serum levels after 30 days of clomiphene use, contributing to estrogenic side effects including gynecomastia and mood changes [14].

Enclomiphene, by containing only the trans-isomer, avoids zuclomiphene accumulation. This is the primary clinical rationale for preferring it over generic clomiphene in men, despite the higher cost.

Cost-Benefit Consideration

Generic clomiphene at 25 mg every other day costs roughly $15, $25/month and raises testosterone similarly in short-term trials [13]. If cost is the overriding concern and estrogenic side effects are absent or acceptable, generic clomiphene is a reasonable alternative your physician can discuss. The FDA-approved status of generic clomiphene also means it may be covered by insurance under off-label use policies, whereas compounded enclomiphene almost certainly will not be [9].

Telehealth Platforms and Enclomiphene Access in 2026

Several telehealth platforms prescribe compounded enclomiphene and coordinate with 503A or 503B pharmacies. The typical workflow is:

1. Online intake form and symptom questionnaire
2. Lab order (patient visits a local draw site or uses an at-home kit)
3. Physician review of labs and video or asynchronous consultation
4. Electronic prescription sent to a compounding pharmacy
5. Monthly or quarterly check-in with lab review

Pricing models vary. Some platforms charge a flat monthly membership ($75, $200/month) that includes medication. Others bill separately for consultation ($50, $150 per visit) and lab work ($80, $200 per panel at direct-pay lab prices).

What to Look for in a Platform

Verify that the platform's physicians are licensed in your state, that the compounding pharmacy is either 503B-registered or accredited by PCAB (Pharmacy Compounding Accreditation Board), and that the protocol includes at least one lab review within the first 90 days. The FDA warns patients about telehealth platforms that prescribe controlled or unapproved substances without adequate clinical evaluation [8].

Patient Populations With Special Access Considerations

Men With Infertility as the Primary Concern

For men seeking to preserve or restore fertility, enclomiphene's mechanism is directly relevant. The American Society for Reproductive Medicine (ASRM) practice committee opinion on male infertility notes that empiric SERM therapy may be considered for idiopathic oligospermia, though evidence from large RCTs is limited [15]. These patients may qualify for fertility benefit coverage under some insurance plans, which could offset part of the cost.

Men Who Have Used Testosterone Therapy Previously

Prior TRT suppresses the HPG axis. Recovery of endogenous testosterone and spermatogenesis after TRT cessation can take 6 to 18 months and may require SERM support [16]. A 2020 review in Translational Andrology and Urology found that post-TRT recovery protocols using clomiphene or enclomiphene reduced median time to testosterone normalization compared with watchful waiting [16]. These patients often have a stronger case for medical necessity documentation when seeking insurance appeals.

Men Over 50

Secondary hypogonadism in older men can coexist with primary testicular failure. Enclomiphene is generally less effective when LH and FSH are already elevated, indicating primary failure. Lab confirmation (elevated LH/FSH with low testosterone) should prompt a different therapeutic approach. SERM therapy in primary hypogonadism is unlikely to be beneficial and is not supported by the Endocrine Society guideline [3].

Regulatory Outlook: Will Enclomiphene Get FDA Approval?

The absence of an approved product is not permanent. As of January 2026, no NDA for enclomiphene is listed as active in the FDA's drug approval database [1]. However, several companies have announced intentions to pursue approval for secondary hypogonadism indications. FDA approval would have several practical consequences:

• A branded product would become available at retail pharmacies
• Insurance coverage would become more feasible
• Compounding under 503A would become restricted (pharmacies cannot compound copies of approved drugs under most circumstances) [6]
• Cost would likely initially increase relative to current compounding prices, then decrease as generics enter

Patients and physicians should monitor the FDA's Drugs@FDA database for NDA submissions [1]. If approval occurs, transitioning to the approved product is advisable for regulatory and quality reasons, even if the short-term cost is higher.

Summary of Access Pathways by Patient Profile

| Patient Profile | Recommended Pathway | Estimated Monthly Cost | |-----------------|--------------------|-----------------------| | Uninsured, cost-sensitive | 503A compounding + HSA/FSA | $30, $65 (after tax benefit) | | Insured, willing to appeal | Insurance prior auth + medical necessity letter | $0, $30 if approved | | Fertility-focused | ASRM-affiliated clinic or fertility trial | $0 (if enrolled in trial) | | Research interest | ClinicalTrials.gov enrollment | $0 | | Highest quality standard | 503B outsourcing facility via telehealth | $80, $150 |

Work with a physician to determine which pathway matches your clinical situation before ordering from any source.